B. Riley lowered the firm’s price target on Agenus to $6 from $8 and keeps a Buy rating on the shares. The company’s Q3 update reaffirms the progression towards global regulatory approvals in multiple solid tumors beginning late 2024 and early 2025, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AGEN:
